The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion.
about
Bioinformatic analysis of HIV-1 entry and pathogenesis.Evolution rescues folding of human immunodeficiency virus-1 envelope glycoprotein GP120 lacking a conserved disulfide bondThe influence of N-linked glycans on the molecular dynamics of the HIV-1 gp120 V3 loop.A non-canonical binding interface in the crystal structure of HIV-1 gp120 core in complex with CD4Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infectionsVariation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis.Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers.Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.Unique C2V3 sequence in HIV-1 envelope obtained from broadly neutralizing plasma of a slow progressing patient conferred enhanced virus neutralization.HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans.Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding siteOccluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice.The W100 pocket on HIV-1 gp120 penetrated by b12 is not a target for other CD4bs monoclonal antibodiesCellular and viral mechanisms of HIV-1 transmission mediated by dendritic cellsHIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation.Only five of 10 strictly conserved disulfide bonds are essential for folding and eight for function of the HIV-1 envelope glycoproteinComparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design.Reconstructing the temporal progression of HIV-1 immune response pathways.HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity.Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5Enhanced macrophage tropism of HIV in brain and lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site antibody b12.Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo.A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the α4β7-binding V2 loop of HIV gp120 in healthy volunteers.HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody 2G12.Heterogeneity in glycan composition on the surface of HIV-1 envelope determines virus sensitivity to lectins.Structural Rearrangements Maintain the Glycan Shield of an HIV-1 Envelope Trimer After the Loss of a Glycan
P2860
Q27693321-CA6F0726-8A41-4896-B00A-79840057DF42Q30157538-2FB45286-623E-4C5A-AB93-3AEBE1E3DD5DQ30356350-840EDA6A-110C-4842-B1D9-FE98C3CB81D9Q33587774-E888A41B-ACAF-4F1C-A428-7FF1EA943D85Q34042642-42CD6F7E-1335-455B-B566-24264D8B0E84Q34170655-95AFC0D4-6B5D-472A-804F-11D509767E48Q34285680-6EE390E1-2C29-4892-9422-2966601EA2BCQ34299053-82F81E75-C526-424F-A074-C780F6A2B254Q34441935-52F85053-E884-45B3-8913-22AFA4F86F38Q34990575-F373FEAC-B60F-48FB-BACF-CEDCE0AA7491Q35192937-7C419687-C8BE-4367-8AF1-79FC3920D14EQ35746244-7E93BCD7-1B87-4C61-AA61-6C74486F1F81Q35799529-D062E9F0-2C98-4AC5-B15C-26365E6E8E39Q36448906-6B279645-356D-4DAA-89E0-56B12AC970EDQ36664069-A79E662E-1A15-4778-908F-E065D11033B8Q36914293-5D437D37-2082-4DC2-BDBA-E7619486A055Q36978861-E20F3FD7-C04A-4867-9C95-73EC9CC30DBDQ37005470-A6620B6D-99AB-42AD-9B7C-B7A75337780FQ37360774-B9969189-0F1E-4847-ADEE-E4DF29933759Q37410770-FD515D4A-2D02-467B-B749-29478C47D165Q38341741-561155E5-6D7E-4514-B1E4-7E9D07419096Q38979760-EC2F1C5A-B69F-4A31-9D64-4CEF524D1A7EQ41611835-C373B00E-21E8-4505-BC3A-D42243F54D67Q42321384-811999DF-5BDC-44D3-98E3-D1BE9DD2672CQ42428236-4EC059C6-FA88-46A4-9463-7CB1E969A5EFQ52341775-0B5BA675-FB05-468D-B9C6-B5DC8A5E43C3Q57292375-2CDDC0C6-6592-423F-8E42-55A2DC877D77
P2860
The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
The carbohydrate at asparagine ...... is involved in immune evasion.
@en
type
label
The carbohydrate at asparagine ...... is involved in immune evasion.
@en
prefLabel
The carbohydrate at asparagine ...... is involved in immune evasion.
@en
P2093
P2860
P356
P1433
P1476
The carbohydrate at asparagine ...... is involved in immune evasion
@en
P2093
Alexei A Nabatov
Ben Berkhout
Dirk Eggink
Els Busser
Fedde Groot
I Marije Liscaljet
Ilja Bontjer
Mark Melchers
Martijn M Dankers
Rogier W Sanders
P2860
P2888
P356
10.1186/1742-4690-5-10
P577
2008-01-31T00:00:00Z
P5875
P6179
1003597736